Skip to main content
Equibles
BDSX logo

BDSX · Biodesix Inc · Metrics

Track BDSX — free

Use BDSX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BDSX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.65 +0.72 (+3.01%)
Rebalance outlook locked
Market Cap
$253.81M
Shares
10.55M
Volume · Oct 22 60.25K Avg daily vol (3M) 99.55K

BDSX metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.93
Market cap
$253.81M

Price action

20 metrics
Price change (1W)
-0.3%
Price change (30D)
-15.0%
Price change (3M)
+11.9%
Price change (6M)
+106.6%
Price change (YTD)
+251.9%
Price change (1Y)
+250.4%
Trailing year
Price change (5Y)
—
52-week high
$30.60
52-week low
$5.46
Change from 52-week high
-21.8%
Change from 52-week low
+338.3%
Annualized volatility
107.8%
Annualized volatility (3M)
71.7%
Beta
1.0
RSI (14D)
39.7
Price vs SMA 50
-10.1%
Price vs SMA 200
+32.0%
Avg volume (3M)
99,554
Relative volume
0.5
Average dollar volume
$2.60M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
10.55M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.7×
reciprocal yield 37.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 40.6%
P / book
27.8
reciprocal yield 3.6%
FCF yield
-8.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.6%
EV / revenue historical average (5Y)
2.4×
reciprocal yield 40.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-20.0%
Trailing 12 months
Net margin
-27.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$20.61M
Net income (TTM)
−$27.76M
Trailing 12 months
Diluted EPS (TTM)
$-3.11
FCF margin
-19.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$11.72
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.35
EBITDA per diluted share (TTM)
$-1.71
Net income per diluted share (TTM)
$-3.17
Operating cash flow per diluted share (TTM)
$-2.29
Free cash flow per diluted share (TTM)
$-2.34
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$1.40
Stock compensation per diluted share (TTM)
$0.47
Book value per share
$-0.30

Growth

11 metrics
Revenue growth YoY
+34.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$102.94M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+40.4%
Year over year · more shares
Revenue CAGR (3Y)
+32.3%
Revenue CAGR (5Y)
+14.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-303.6%
Return on assets
-29.1%
Debt / equity
5.5
Current ratio
2.8
EBITDA (TTM)
−$15.03M
Free cash flow (TTM)
−$20.24M
Quick ratio
2.8
Interest coverage
-2.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$20.00M
Latest balance sheet
Cash & equivalents
$30.00M
Total assets
$95.33M
Total debt
$50.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.83M
Capital expenditures (TTM)
$412,000
R&D (TTM)
$12.28M
SG&A (TTM)
$93.23M
Stock compensation (TTM)
$4.06M
R&D / revenue
11.9%
Stock compensation / revenue
3.9%

Ownership (13F)

9 metrics
13F filers
45
13F filer change QoQ
+5
Institutional ownership
41.4%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
22.4%
Private-fund adviser ownership
8.8%
Active holders' share change QoQ
+15.8%
Holder tenure
5.0
Price vs estimated holder cost
+12.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.2%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.8 days to cover
Days to cover
1.8d
Short-squeeze score
39 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1439725 CUSIP 09075X207 13F (30d) 3 filings 3 filers Visit website Investor relations